[EN] COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS<br/>[FR] COMPOSÉS ET COMPOSITIONS SERVANT DE MODULATEURS DE L'ACTIVITÉ DES TLR
申请人:IRM LLC
公开号:WO2009111337A1
公开(公告)日:2009-09-11
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
申请人:Cortez Alex
公开号:US20110081365A1
公开(公告)日:2011-04-07
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X
3
is N; X
4
is N Or CR
3
; X
5
is —CR
4
═CR
5
.
Biologically active 6-aminophenanthridines were prepared in a single step procedure: Metal amides in liquid ammonia promoted the condensation of anilines with 2-chloro-benzonitriles. 6-Aminophenanthridines were isolated in moderate yield. (C) 2004 Elsevier Ltd. All rights reserved.
CRIBLAGE DE MOLECULES A ACTIVITE ANTI-PRION : KITS, METHODES ET MOLECULES CRIBLEES
申请人:CENTRE NATIONAL DE
LA RECHERCHE SCIENTIFIQUE (CNRS)
公开号:EP1551992B1
公开(公告)日:2006-12-27
Screening molecules with anti-prion activity: kits, methods and screened molecules
申请人:Blondel Marc
公开号:US20060172337A1
公开(公告)日:2006-08-03
The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates.